logo
Astronomers capture 1st close-up photograph of new interstellar visitor

Astronomers capture 1st close-up photograph of new interstellar visitor

CBC17-07-2025
It's out of this world. Or, more accurately, this solar system.
On July 1, astronomers discovered an object near the orbit of Jupiter that was somewhat peculiar. It had a strange orbit, one that didn't take it around the sun like most asteroids or comets.
Eventually it was confirmed that this object — named 3I/ATLAS, or C/2025 N1 (ATLAS) — was an interstellar visitor.
Now, using the U.S. National Science Foundation's (NSF) Gemini North telescope in Hawaii, astronomers have captured the first detailed image of this cosmic interloper.
"We look forward to a bounty of new data and insights as this object warms itself on sunlight before continuing its cold, dark journey between the stars," Martin Still, NSF program director for the International Gemini Observatory, said in a statement.
The comet will continue to be visible in large telescopes until September, after which it will be lost in the sun's glare.
Learning more about the comet
"As this is only our third interstellar visitor ever discovered, we're excited to learn about this entirely new class of object," Paul Wiegert, an astronomy professor at Western University, told CBC News in an email.
Astronomers like to study comets and asteroids as they are left over from our solar system's earliest formation and can reveal what conditions were like at the time. Being able to study something from outside of our neighbourhood could potentially provide more knowledge about other star systems.
Current observations suggest the comet is roughly 20 kilometres in diameter, far larger than the previous two interstellar comets astronomers observed passing through our solar system.
The first comet was 'Oumuamua, which had a measly diameter of 200 metres. The second was 2I/Borisov, which was one kilometre in diameter.
The fact that 3I/ATLAS is so large is a boon to astronomers: It makes it easier to study, particularly as it nears Earth. It will make a close approach in December, but poses no threat.
A recent study presented by author Matthew Hopkins at the Royal Astronomical Society's National Astronomy Meeting 2025 in Durham, England, suggests that this new visitor may be the oldest comet ever seen.
He estimates its origin to be from a part of our galaxy that is home to ancient stars, and says that it could be seven billion years old, far older than our galaxy's 4.5 billion years.
And this new visitor is hustling: when it was discovered, it was travelling at roughly 61 kilometres per second.
How they know it's not from our neighbourhood
Astronomers can determine the origin of comets or asteroids based on their orbits' eccentricity, or how stretched out its path is.
An eccentricity of 0 means it is a perfectly circular orbit. An eccentricity greater than one means the orbit does not circle around the sun, and the higher the value, the more stretched out the orbit.
WATCH | Orbit of third-known interstellar object:
Orbit of third-known interstellar object
14 hours ago
In 3I/ATLAS's case, its orbit is 6.2, which is how astronomers knew that it came from beyond the solar system. For comparison, 'Oumuamua had an eccentricity of 1.2 and 2I/Borisov's eccentricity was 3.6.
Currently, this new comet is still within Jupiter's orbit, roughly 465 million kilometres from Earth. It will make its closest approach to our planet on Dec. 19, at a distance of roughly 270 million kilometres.
It will reach its closet point to the sun on Oct. 30 at a distance of 210 million kilometres, which will be just inside the orbit of Mars.
Though astronomers have quickly learned some things about this newest interloper, they hope to learn more over time.
"This one seems much like a comet from our own solar system. That is, mostly made of ice which has been frozen for billions of years as it wandered the galaxy, but now [is] starting to gently turn to vapour in the light of our sun. This makes 3I/ATLAS look fuzzy with a tail, visible in the image," Wiegert said.
"But we really don't know if it is like one of our comets (which are leftover building block from when the Earth and planets formed) or something completely different."
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Pop is in the spotlight yet again. This time, for its ability to disrupt gut bacteria and immunity
Pop is in the spotlight yet again. This time, for its ability to disrupt gut bacteria and immunity

National Post

time11 minutes ago

  • National Post

Pop is in the spotlight yet again. This time, for its ability to disrupt gut bacteria and immunity

Pop has been a hot topic over the past few weeks. First, U.S. President Donald Trump waded into MAHA — Make America Healthy Again — waters by saying Coca-Cola was swapping high-fructose corn syrup for cane sugar. 'It's just better!' he posted on social media. (Health experts say it's not. There's no nutritional difference between the two.) Article content Drinking pop has long been linked to adverse health effects, such as obesity, Type 2 diabetes and heart disease. Added sugars (whatever their source) are the primary culprit, yet 'diet sodas, which have been found to increase hunger and disrupt metabolism, are not any better,' according to UCLA Health. A new study suggests another pop-consumption concern: sugary drinks disrupt gut bacteria and immunity. Article content Article content But it's not all doom and gloom, say researchers from the Ruth and Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology. The study published in Nature Communications found that though drinking pop sweetened with white sugar alters the DNA of gut bacteria and affects the immune system, once sugar consumption stops, the impacts are reversible. Article content Article content 'Gut bacteria are important members of the microbial community within our body, i.e., the microbiome. These bacteria, which have co-evolved with humans for generations, are so essential to human health in general and to the development of the immune system in particular that we cannot function without them,' says a press release about the research. Studies have shown that diet influences microbiome composition and overall functionality, write the researchers, led by professor Naama Geva-Zatorsky and Ph.D. student Noa Gal-Mandelbaum. In contrast, research on the impact of what we eat on the functionality of specific gut bacteria is 'relatively scarce.' Article content Article content The current research builds on a previous study by the Geva-Zatorsky Lab, which identified DNA inversions ('rapid genetic switches') as one way gut bacteria respond to and protect themselves when facing environmental changes. To understand how dietary factors affect these inversions, the study focused on Bacteroides thetaiotaomicron. Article content Article content The researchers say that this 'prominent gut member' plays a role in preventing gut inflammation, preserving its mucus layer and protecting the body from pathogens. By studying the effects of different dietary components on the bacteria's DNA, in vitro, in mice and in humans, the researchers found that white sugar consumption created DNA inversions, which impacted the immune system. Article content In a social media post, Technion said, 'This discovery highlights the deep connection between our diet, microbiome and health — and opens the door to personalized nutrition for a stronger immune system.' Article content

Pluristyx Completes Investment Round to Expand Product Portfolio and Commercial Operations
Pluristyx Completes Investment Round to Expand Product Portfolio and Commercial Operations

National Post

time4 hours ago

  • National Post

Pluristyx Completes Investment Round to Expand Product Portfolio and Commercial Operations

Article content SEATTLE — Pluristyx, a leading provider of induced pluripotent stem cell (iPSC) technologies and proprietary gene editing solutions, today announced the successful close of its most recent round of funding led by BioLife Solutions, the global leader in cryopreservation technologies and systems that support cell and gene therapy (CGT) manufacturing, and BroadOak Capital Partners, a specialist investor in the life science tools and services industry. Article content The newly raised capital will enable Pluristyx to expand inventory with new clinical grade cell lines incorporating Pluristyx's proprietary FailSafe® and iACT™ engineering and hypoimmune genetic edits in its best-in-class, polyclonal, synthetic RNA reprogramed iPSCs. These proprietary cells are specifically designed to support making next-generation genetically engineered, stem cell-derived therapies and support uniquely safe, effective, and scalable living medicines. The funding will also support Pluristyx's recently launched PluriForm ™ kit, which provides researchers with streamlined tools for generating organoids and other complex test systems. Article content 'We are incredibly excited for the successful close of this round and gratified to have industry leaders and peers validate our vision with their investment,' said Benjamin Fryer, PhD, CEO of Pluristyx. 'The support from our Seattle area neighbor, BioLife Solutions, and continued support from our colleagues at BroadOak Partners will allow us to manufacture, commercialize, and distribute our innovative solutions and help our customers solve critical industry challenges.' Article content Roderick de Greef, BioLife's Chairman and CEO, remarked, 'We have known and worked with the founding team at Pluristyx for many years, and have a great deal of respect for their scientific expertise in cell therapy. Their recent development of an iPSC-based biological assay for organoid manufacturing dovetails with our interest in exploring biological assays more broadly as a product portfolio adjacency.' Article content 'We are excited to continue our support of Dr. Fryer and the entire Pluristyx team,' said Daniel Friedman, Principal at BroadOak Capital Partners. 'Pluristyx is differentiated by its suite of proprietary technologies that directly address some of the most critical scientific challenges of the iPSC field.' Article content iPSCs are unique tools and building blocks for medicines. In addition to applications for innovative new toxicology, safety, and efficacy assays to replace animal models, Pluristyx's products are the ideal universal raw material to produce living medicines to cure currently untreatable diseases. This strategic investment will enable Pluristyx to be the industry leader offering the highest quality stem cells available anywhere. Article content About BioLife Solutions Article content BioLife Solutions is a leading developer and supplier of bioproduction products and services for the cell and gene therapy (CGT) and broader biopharma markets. Our expertise facilitates the commercialization of new therapies by supplying solutions that maintain the health and function of biologic materials during collection, development, storage, and distribution. For more information, please visit or follow BioLife on LinkedIn and X. Article content About BroadOak Capital Partners Article content BroadOak Capital Partners is a boutique financial institution that provides direct investment and investment banking services to companies in the life science tools, diagnostics, and biopharma services sectors. BroadOak has led or participated in investments in over 70 companies across the life sciences industry. For more information, visit Article content Pluristyx is dedicated to enabling the development of next-generation cell-based tools and therapies. PluriKit™, PluriForm™ Organoids, and PluriBank™ stem cells incorporating safety and tolerance features like FailSafe®, iACT™, and hypoimmune engineering streamline developers' path to the clinic and approval. Pluristyx's iPSC lines, backed by an FDA registered drug master file, with platform genetic engineering are available 'off-the-shelf' along with comprehensive support services to accelerate the creation of novel diagnostics, screening and safety testing, and curative treatments. For more information, visit Article content Article content Article content Article content

Hyperfine Swoop® AI-Powered Portable MRI System Demonstrates 100% Sensitivity for ARIA-E Detection in New Data Presented at the 2025 Alzheimer's Association International Conference
Hyperfine Swoop® AI-Powered Portable MRI System Demonstrates 100% Sensitivity for ARIA-E Detection in New Data Presented at the 2025 Alzheimer's Association International Conference

National Post

time5 hours ago

  • National Post

Hyperfine Swoop® AI-Powered Portable MRI System Demonstrates 100% Sensitivity for ARIA-E Detection in New Data Presented at the 2025 Alzheimer's Association International Conference

Article content Interim results from the CARE PMR study support the use of ultra-low-field MRI as a triage tool for monitoring patients on amyloid-targeting therapies. Article content TORONTO — Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable MRI system for the brain—the Swoop ® system—announced promising early results from the CARE PMR (Capturing ARIA Risk Equitably with Portable MR) study presented at the 2025 Alzheimer's Association International Conference in Toronto, Canada. Article content Researchers from the Benzinger Lab at Washington University School of Medicine in St. Louis reported interim results from 31 Alzheimer's patients undergoing Lecanemab therapy. Participants were scanned using the Swoop ® system within one week of their clinical high-field MRI scans, as part of the safety monitoring protocol required by the FDA when it approved Lecanemab. Article content The Swoop ® system achieved 100% sensitivity in detecting mild to moderate ARIA-E, a condition marked by cerebral edema. Researchers note that while ultra-low-field MRI is promising as a triage tool to screen for ARIA-E, high-field MRI may remain necessary for comprehensive evaluation in some cases. Article content Appropriate use guidelines for amyloid-targeting therapies, including Lecanemab and Donanemab, require MRI safety monitoring at multiple, specific intervals throughout the course of therapy. However, regular screening with conventional MRI systems is often hindered by high costs, scheduling delays, and logistical challenges for both patients and caregivers. The Swoop ® system addresses these barriers by offering an affordable, portable imaging solution that is readily available to patients at the point of care, such as neurology offices and infusion clinics. Dr. Tammie Benzinger, principal investigator of the study, noted, 'This research could help alleviate the burden on families and facilities and improve overall access to care. We are hoping to expand the project to Washington University's Medical Campus to include community sites offering infusion therapy for early Alzheimer's disease.' Article content These findings from the CARE PMR study underscore the potential of portable MRI to transform ARIA-E monitoring and expand access to care. The Swoop ® system enables clinicians to confidently detect ARIA-E, while offering patients and caregivers the convenience of point-of-care screening, eliminating the need for separate imaging appointments. 'We are proud to collaborate with leading clinicians and researchers who share our vision of advancing Alzheimer's care through accessible innovation,' said Edmond Knopp, MD, Chief Medical Officer at Hyperfine. Article content The CARE PMR study is a collection of data from multiple sites assessing the clinical utility and workflow benefits of using Swoop ® system images to detect amyloid-related imaging abnormalities (ARIA) in Alzheimer's patients receiving amyloid-targeting therapy. It is funded by the Alzheimer's Association and the American Society of Neuroradiology. Article content The Swoop ® Portable MR Imaging ® Systems are U.S. Food and Drug Administration (FDA) cleared for brain imaging of patients of all ages. They are portable, ultra-low-field magnetic resonance imaging devices for producing images that display the internal structure of the head where full diagnostic examination is not clinically practical. When interpreted by a trained physician, these images provide information that can be useful in determining a diagnosis. Article content About Hyperfine, Inc. Article content Hyperfine, Inc. (Nasdaq: HYPR) is the groundbreaking health technology company that has redefined brain imaging with the Swoop ® system—the first FDA-cleared, portable, ultra-low-field, magnetic resonance brain imaging system capable of providing imaging at multiple points of professional care. The mission of Hyperfine, Inc. is to revolutionize patient care globally through transformational, accessible, clinically relevant diagnostic imaging. Founded by Dr. Jonathan Rothberg in a technology-based incubator called 4Catalyzer, Hyperfine, Inc. scientists, engineers, and physicists developed the Swoop ® system out of a passion for redefining brain imaging methodology and how clinicians can apply accessible diagnostic imaging to patient care. For more information, visit Article content The Hyperfine logo, Swoop, and Portable MR Imaging are registered trademarks of Hyperfine, Inc. The Swoop logo, Optive AI logo, and Optive AI are trademarks of Hyperfine, Inc. Article content Forward-Looking Statements Article content This press release includes 'forward-looking statements' within the meaning of the 'safe harbor' provisions of the Private Securities Litigation Reform Act of 1995. Actual results of Hyperfine, Inc. (the 'Company') may differ from its expectations, estimates and projections and consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as 'expect,' 'estimate,' 'project,' 'budget,' 'forecast,' 'anticipate,' 'intend,' 'plan,' 'may,' 'will,' 'could,' 'should,' 'believes,' 'predicts,' 'potential,' 'continue,' and similar expressions (or the negative versions of such words or expressions) are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, the Company's goals and commercial plans, the benefits of the Company's products and services, and the Company's future performance and its ability to implement its strategy. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results. Most of these factors are outside of the Company's control and are difficult to predict. Factors that may cause such differences include, but are not limited to: the success, cost and timing of the Company's product development and commercialization activities, including the degree that the Swoop ® system is accepted and used by healthcare professionals; the impact of COVID-19 on the Company's business; the inability to maintain the listing of the Company's Class A common stock on the Nasdaq; the Company's inability to grow and manage growth profitably and retain its key employees; changes in applicable laws or regulations; the inability of the Company to raise financing in the future; the inability of the Company to obtain and maintain regulatory clearance or approval for its products, and any related restrictions and limitations of any cleared or approved product; the inability of the Company to identify, in-license or acquire additional technology; the inability of the Company to maintain its existing or future license, manufacturing, supply and distribution agreements and to obtain adequate supply of its products; the inability of the Company to compete with other companies currently marketing or engaged in the development of products and services that the Company is currently marketing or developing; the size and growth potential of the markets for the Company's products and services, and its ability to serve those markets, either alone or in partnership with others; the pricing of the Company's products and services and reimbursement for medical procedures conducted using the Company's products and services; the Company's estimates regarding expenses, revenue, capital requirements and needs for additional financing; the Company's financial performance; and other risks and uncertainties indicated from time to time in Company's filings with the Securities and Exchange Commission, including those under 'Risk Factors' therein. The Company cautions readers that the foregoing list of factors is not exclusive and that readers should not place undue reliance upon any forward-looking statements, which speak only as of the date made. The Company does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based. Article content Article content Article content Article content Media Contact Article content Article content Devin Zell Article content Article content Hyperfine Article content Article content dzell@ Article content Investor Contact Article content Article content Webb Campbell Article content Article content

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store